What is the most important outcome parameter in ankylosing spondylitis?

Rheumatology

Volumn 47, Issue 12, 2008, Pages 1738-1740

  Braun, J ^a,b   Sieper, J ^c  

^a RHEUMAZENTRUM RUHRGEBIET   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB; NONSTEROID ANTIINFLAMMATORY AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANKYLOSING SPONDYLITIS; DISEASE ACTIVITY; DISEASE COURSE; EDITORIAL; FUNCTIONAL ASSESSMENT; HUMAN; MYELITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; OSSIFICATION; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; SEX DIFFERENCE; SPINE MOBILITY; TREATMENT RESPONSE;

HUMANS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 56649123536     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken357     Document Type: Editorial

References (56)

1. Braun J, Sieper J. Ankylosing spondylitis. The Lancet 2007;369:1379-90.
2. Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory back pain in ankylosing spondylitis - a reassessment of the clinical history for classification and diagnosis. Arthritis Rheum 2006;54:569-78.
3. Zink A, Braun J, Listing J, Wollenhaupt J. Disability and handicap in rheumatoid arthritis and ankylosing spondylitis - results from the German rheumatological database. German Collaborative Arthritis Centers. J Rheumatol 2000;27:613-22.
4. Zochling J, Bohl-Buhler MH, Baraliakos X, Feldtkeller E, Braun J. Nonsteroidal antiinflammatory drug use in ankylosing spondylitis-a population-based survey. Clin Rheumatol. 2006;6:794-800.
5. Song IH, Poddubnyy DA, Rudwaleit M, Sieper J. Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008;58:929-38.
6. Barkham N, Kong KO, Tennant A et al. The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 2005;44:1277-81.
7. Vander Cruyssen B, Ribbens C, Boonen A. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis 2007;66:1072-7.
8. Zochling J, van der Heijde D, Burgos-Vargas R. 'ASsessment in AS' international working group; European League Against Rheumatism. ASAS/ EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2006; 65:442-52.
9. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D; ASAS Working Group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20.
10. Braun J, Brandt J, Listing J et al. Treatment of active ankylosing spondylitis with infliximab - a double-blind placebo controlled multicenter trial. Lancet 2002;359:1187-93.
11. Brandt J, Kariouzov A, Listing J et al. Six months results of a German double-blind placebo controlled clinical trial of etanercept in active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75.
12. van der Heijde D, Dijkmans B, Geusens P et al., ATLAS Study Group. Efficacy and safety of infliximab in patients with ankylosing spondylitis - results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum. 2005;52:582-91.
13. van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, doubleblind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46.
14. Haibel H, Rudwaleit M, Brandt HC et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: Clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. Arthritis Rheum 2006;54:678-81.
15. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-α antibody infliximab inpatients with ankylosing spondylitis over 3 years. Rheumatology 2005;44:670-6.
16. Davis JC, van der Heijde DM, Braun J et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis. Advance Access published October 29, 2007.
17. Braun J, Baraliakos X, Listing J, et al. Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 2008;67:340-5.
18. Brandt J, Listing J, Sieper J, Rudwaleit M, van der Heijde D, Braun J. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44.
19. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
20. Calin A, Garrett S, Whitelock H et al. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
21. Anderson JJ, Baron G, van der Heijde D, Felson DT, Dougados M. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
22. Braun J, McHugh N, Singh A, Wajdula JS, Sato R. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50mg once-weekly and 25mg twice-weekly. Rheumatology 2007;46:999-1004.
23. Davis JC Jr, Revicki D, van der Heijde DM et al. Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: Results from a randomized controlled study. Arthritis Rheum 2007;57:1050-7.
24. van der Heijde D, Han C, DeVlam K et al. Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: Results from a randomized, placebo-controlled trial. Arthritis Rheum 2006;55:569-74.
25. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70.
26. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J. MRI in predicting a major clinical response to anti-TNF-treatment in ankylosing spondylitis. Ann Rheum Dis 2008;67:1276-81.
27. Braun J, Baraliakos X, Golder W et al. MRI examinations of the spine in patients with ankylosing spondylitis (AS) before and after infliximab therapy after evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
28. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis before and during therapy with etanercept. Ann Rheum Dis 2005;64:1305-10.
29. Lambert RG, Salonen D, Rahman P et al. Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: A multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2007;56:4005-14.
30. Braun J, Landewe R, Hermann KG et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: Results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 2006;54:1646-52.
31. Baraliakos X, Brandt J, Listing J et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: Clinical and magnetic resonance imaging data. Arthritis Rheum 2005;53:856-63.
32. Sieper J, Baraliakos X, Listing J et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 2005;44:1525-30.
33. Braun J, Bollow M, Sieper J. Radiologic diagnosis and pathology of the spondyloarthropathies. Rheum Dis Clin North Am 1998;24:697-735.
34. Baraliakos X, Listing J, Rudwaleit M et al. Progression of radiographic damage in patients with ankylosing spondylitis: Defining the central role of syndesmophytes. Ann Rheum Dis 2007;66:910-5.
35. Baraliakos X, Listing J, Brandt J et al. Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology 2007;46:1450-3.
36. van der Heijde D, Landewé R, Einstein S et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
37. van der Heijde D, Landewé R, Braun J et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with infliximab. Arthritis Rheum 2008, in press.
38. Sieper J, Appel H, Braun J, Rudwaleit M. Critical appraisal of assessment of structural damage in ankylosing spondylitis: Implications for treatment outcomes. Arthritis Rheum 2008;58:649-56.
39. Baraliakos X, Landewé R, Hermann KG et al. Inflammation in ankylosing spondylitis: A systematic description of the extent and frequency of acute spinal changes using magnetic resonance imaging. Ann Rheum Dis 2005;64:730-4.
40. Creemers MC, Franssen MJ, van't Hof MA, Gribnau FW, van de Putte LB, van Riel PL. Assessment of outcome in ankylosing spondylitis: An extended radiographic scoring system. Ann Rheum Dis 2005;64:127-9.
41. Wanders AJ, Landewé RB, Spoorenberg A et al. What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 2004;50:2622-32.
42. Diarra D, Stolina M, Polzer K et al. Dickkopf-1 is a master regulator of joint remodeling. Nat Med 2007;13:156-63.
43. Wanders A, Heijde D, Landewé R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: A randomized clinical trial. Arthritis Rheum 2005;52:1756-65.
44. Simon AM, Manigrasso MB, O'Connor JP. Cyclo-oxygenase 2 function is essential for bone fracture healing. J Bone Miner Res 2002;17:963-76.
45. Fransen M, Neal B. Non-steroidal anti-inflammatory drugs for preventing heterotopic bone formation after hip arthroplasty. Cochrane Database Syst Rev 2004;(3): CD001160.
46. Smolen JS, Han C, Bala M et al., ATTRACT Study Group. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthritis Rheum 2005;52:1020-30.
47. Landewé R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate: Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. Arthritis Rheum 2006;54:3119-25.
48. Wanders A, Landewé R, Dougados M, Mielants H, van der Linden S, van der Heijde D. Association between radiographic damage of the spine and spinal mobility for individual patients with ankylosing spondylitis: Can assessment of spinal mobility be a proxy for radiographic evaluation? Ann Rheum Dis 2005;64:988-94.
49. Vosse D, van der Heijde D, Landewé R et al. Determinants of hyperkyphosis in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:770-4.
50. van Echteld I, Cieza A, Boonen A et al. Identification of the most common problems by patients with ankylosing spondylitis using the International Classification of Functioning, Disability and Health. J Rheumatol 2006;33:2475-83.
51. Tubach F, Pham T, Skomsvoll JF et al. Stability of the patient acceptable symptomatic state over time in outcome criteria in ankylosing spondylitis. Arthritis Rheum 2006;55:960-3.
52. Braun J, Deodhar A, Dijkmans B et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis through 2 years. Arthritis Rheum 2008, in press.
53. Baraliakos X, Listing J, Von der Recke, A, Braun J. The natural course of radiographic progression in ankylosing spondylitis - evidence for non-linear progression in a large proportion of patients. Ann Rheum Dis 2008.
54. Heiberg MS, Koldingsnes W, Mikkelsen K et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study. Arthritis Rheum 2008;59:234-40.
55. Dagfinrud H, Kvien TK, Hagen KB. Physiotherapy interventions for ankylosing spondylitis. Cochrane Database Syst Rev 2008;(1):CD002822.
56. Lubrano E, D'Angelo S, Parsons WJ et al. Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: A pilot study. J Rheumatol 2006;33:2029-34.